Priority Date: 12.12.11 (WO 2011IB03253)

ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

  • Application ID: EP12799204
  • Status: The patent has been granted

Attorney

no operation time available
1283.74
4 offices
active in Legal Services

Specialization

This EP application has the IPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE). Lavoix is specialised in A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE). Here you find a list of all patent agent firms which are specialized in this IPC class. For a similar patent, they might be a good choice.

Timeline

  • 12.12.2011 - Priority Date (WO 2011IB03253)
  • 20.06.2013 - Publication A1 (WO2013087725)
  • 22.10.2014 - Publication A1 (EP2790718)
  • 07.02.2018 - Publication B1 (EP2790718)

IPC Classification